Literature DB >> 25516445

Overexpression of PGC1α and accumulation of p62 in apocrine carcinoma of the breast.

Fumi Fuchinoue1, Yukari Hirotani, Yoko Nakanishi, Hiromi Yamaguchi, Haruna Nishimaki, Hiroko Noda, Xiao Yan Tang, Misato Iizuka, Sadao Amano, Masahiko Sugitani, Norimichi Nemoto, Shinobu Masuda.   

Abstract

Apocrine carcinoma is categorized as a special type of breast carcinoma because of its specific morphological features. To clarify the characteristics of apocrine carcinoma from the point of view of the mitochondrial profile, we conducted a comparative study between apocrine and non-apocrine carcinomas. The expressions of mitochondrial related factors (PGC1α, Nrf1, Nrf2, mtTFA and COX4) were examined in a testing set of breast cancer tissue. Apocrine carcinomas showed a clear tendency towards higher mRNA expression levels of PGC1α than non-apocrine carcinomas. The expression of the selected factor, PGC1α, as well as that of p62 was further examined. The results revealed that apocrine carcinomas showed a higher immunohistochemical positivity rate for PGC1α (21.3% vs. 3.2%; P = 0.008), and that the mRNA expression level of PGC1α was significantly higher in apocrine carcinoma than in non-apocrine carcinoma (P = 0.007). The immunohistochemical positivity rate for p62 protein was also higher in apocrine carcinomas (44.7% vs. 21.0%; P = 0.015), although no significant difference in the p62 mRNA expression level was detected between the two types of carcinoma (P = 0.633). In conclusion, this study revealed that apocrine carcinoma overexpressed PGC1α contributing to mitochondrial biogenesis, and also p62 protein accumulation.
© 2014 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  PGC1 alpha; apocrine carcinoma; mitochondria; p62

Mesh:

Substances:

Year:  2014        PMID: 25516445     DOI: 10.1111/pin.12235

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Increased expression of mitochondrial transcription factor A and nuclear respiratory factor-1 predicts a poor clinical outcome of breast cancer.

Authors:  Wei Gao; Meihong Wu; Ning Wang; Yingyi Zhang; Jing Hua; Gusheng Tang; Yajie Wang
Journal:  Oncol Lett       Date:  2017-11-24       Impact factor: 2.967

Review 2.  Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored.

Authors:  Edit Mikó; Tünde Kovács; Éva Sebő; Judit Tóth; Tamás Csonka; Gyula Ujlaki; Adrienn Sipos; Judit Szabó; Gábor Méhes; Péter Bai
Journal:  Cells       Date:  2019-03-29       Impact factor: 6.600

3.  Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma.

Authors:  Weiwei Liang; Fangfang Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

Review 4.  Sequestosome 1/p62: A multitasker in the regulation of malignant tumor aggression (Review).

Authors:  Jinlong Tang; Yuan Li; Shuli Xia; Jinfan Li; Qi Yang; Kefeng Ding; Honghe Zhang
Journal:  Int J Oncol       Date:  2021-08-20       Impact factor: 5.650

5.  p62 Regulates the Proliferation of Molecular Apocrine Breast Cancer Cells.

Authors:  Fumi Nozaki; Yukari Hirotani; Yoko Nakanishi; Hiromi Yamaguchi; Haruna Nishimaki; Hiroko Noda; Xiaoyan Tang; Hisae Yamamoto; Atsuko Suzuki; Toshimi Seki; Shinobu Masuda
Journal:  Acta Histochem Cytochem       Date:  2016-08-03       Impact factor: 1.938

6.  Disruption of mitochondrial homeostasis with artemisinin unravels anti-angiogenesis effects via auto-paracrine mechanisms.

Authors:  Kuan-Hao Tsui; Meng-Yu Wu; Li-Te Lin; Zhi-Hong Wen; Yi-Han Li; Pei-Yi Chu; Chia-Jung Li
Journal:  Theranostics       Date:  2019-09-17       Impact factor: 11.556

7.  Triple-Negative Apocrine Breast Carcinoma Has Better Prognosis despite Poor Response to Neoadjuvant Chemotherapy.

Authors:  Taobo Hu; Yiqiang Liu; Jinbo Wu; Xuejiao Lina Hu; Guiyang Zhao; Baosheng Liang; Shu Wang; Mengping Long
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.